Industry: Health care Region: France Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
An innovative biotechnology company in France, focusing on the development of innovative gene therapy in the heart field, was co-founded by experts in the field of heart regeneration. Relying on international scientific research achievements, the company is committed to preventing the disease from worsening to heart failure by promoting myocardial cell regeneration and inhibiting cardiac fibrosis, and improving heart function from the root, so as to significantly improve the life span and quality of life of patients with heart disease. Since its establishment, the company has obtained the deeptech label and a number of scientific research and industrial support, and actively promoted preclinical research, committed to providing a new treatment for major diseases such as heart failure.
Introduction to core technologies:
Adeno-associated virus (AAV) is used as a delivery vector to introduce specific growth factors into the heart. This mechanism has two major functions:
1. Promote the regeneration of myocardial cells: help the damaged myocardial tissue recover its contraction and pumping function.
2. Inhibit cardiac fibrosis: reduce cardiac stiffness and functional degradation, thus improving the overall cardiac performance.
This dual-action mechanism makes it different from traditional medicine or surgical therapy, and pays more attention to the fundamental repair of heart function.
Cooperation mode:
To seek partners interested in innovative cardiac treatment technology in the field of medical research.